Marguerite Davis, PhD, PMP

Clinical Data Analyst

Marguerite Davis is a clinical data analyst at Foresite Capital and contributes to due diligence and research and development evaluation of investment opportunities. She joined the investment team in 2022.

Marguerite brings scientific expertise, project and alliance management experience from both academia and industry to Foresite Capital. In her prior role as R&D Operations Director at Cabaletta Bio, she managed several cross-functional teams spanning labs at PENN and Cabaletta, commercial manufacturing facilities and clinical sites and supported regulatory submissions for autologous cell therapies for auto-immune disease. Previously, she spent five years as senior project manager for a wide range of rare disease focused programs at the Gene Therapy Program within University of Pennsylvania. She implemented nonclinical partnerships, regulatory submissions and early BD for multiple emergent start-up gene therapy companies including RegenxBio and Passage Bio.

She earned a PhD from the Chemistry and Biochemistry Department at University of Delaware and completed postdoctoral studies within the Department of Pharmacology and Physiology at Drexel University. Her research focused on the role of mRNA degradation in injury-induced regeneration of the peripheral nervous system and microRNAs as biomarkers and therapeutics in inflammatory and neuropathic pain.


  • Managed workflow and integrated information across functional teams for more than 20 cell and gene therapies in the rare disease space, 10 of which are currently in Phase I/II clinical trials
  • Created product development plans and risk management tracking for multiple assets with Orphan and Fast Track Designations; onboarded tools and implemented best practices to increase communication, preserve and organize institutional knowledge
  • BS in Chemistry from University of the Ozarks, PhD in Biochemistry from University of Delaware; certified Project Management Professional since 2018